Latest Conference Articles

Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Dr. Blackwell Discusses the T-DM1 EMILIA Trial

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Dr. Rummel on Treanda Plus Rituxan in Indolent Lymphoma

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

Bendamustine Superiority in Lymphoma Regimen Confirmed

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

With Continuous Hormonal Therapy, Certain Men With Prostate Cancer Get Marked Boost in Survival

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Pujade-Lauraine on the AURELIA Bevacizumab Trial

Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Dr. Topalian on the PD-1 Targeted Therapy BMS-936558

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

Avastin Delays Disease Progression in Platinum-Resistant Ovarian Cancer

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

Large Study of ALL Patients Finds Lower Survival in Adolescent and Young Adult Patients

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

PD-1 Immunotherapy Makes Strong Showing in Three Tumor Types

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Rotkowitz on BRAF/MEK Combination Side Effects

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Analysts, Companies Highlight Key ASCO Research

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

2012 ASCO Pre-Meeting Video Coverage

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

Advanced Coverage Recap: 2012 ASCO Annual Meeting

On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.

Dr. Goy Highlights Research From the 2012 ASCO Meeting

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

Dr. Gomella on the Unique Attributes of Neoadjuvant Zytiga

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

Dr. Ladenson on Diagnosis of Thyroid Nodules

Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules

Carriers of Mutation Responsible for Multiple Endocrine Neoplasia Can Face Difficult Choices

Results of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.

Researchers Find Regional Differences in Stage of Presentation and Survival of Individuals With Thyroid Cancer

Patients are more likely to present with regional or distant metastases and experience lower rates of cancer-free survival depending on where they live.

Genetic Data Points to Potential New Therapeutic Target for Adrenocortical Carcinoma

Researchers find that overexpression of a specific gene is associated with poor survival in patients with adrenocortical carcinoma.

Why Medical Tattoos Shouldn't Be Taboo

Another presentation at the AACE meeting on Thursday featured Dr. Saleh Aldasouqi, FACE, ECNU, discussing a topic that is not heard about too often in the medical world: tattoos.

Telemedicine a Valuable Way to Deliver Healthcare

Patients who live far from medical facilities benefit from having "virtual" conversations with their doctors and are comfortable with that arrangement.

AACE 21st Annual Scientific and Clinical Congress Slideshow

Photos taken from the AACE 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012.

Oncology Posters Presented at Annual Endocrinology Meeting

A look at two poster presentations from the AACE meeting focusing on insular carcinoma and medullary thyroid cancer.

Dr. Rotkowitz on the Dabrafenib/Trametinib Combination

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma

Neoadjuvant Zytiga Helps Eliminate Some Patients' Prostate Tumors

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations

A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.

Olanzapine Proves Effective in Breakthrough CINV

Olanzapine, an antipsychotic medication that is often used off-label, has proved highly effective in controlling breakthrough chemotherapy-induced nausea and vomiting.